DOI: 10.5593/sgem2017/61/S25.134


N. Zubenko, K. Bekesheva, I. Korotetskiy, R. Toxanbayev, G. Ustenova
Tuesday 12 September 2017 by Libadmin2017

References: 17th International Multidisciplinary Scientific GeoConference SGEM 2017, www.sgem.org, SGEM2017 Conference Proceedings, ISBN 978-619-7408-12-6 / ISSN 1314-2704, 29 June - 5 July, 2017, Vol. 17, Issue 61, 1025-1034 pp, DOI: 10.5593/sgem2017/61/S25.134


Background: Influenza A viruses continue to be the main cause of major epidemics, accompanied by high mortality. The vaccinal prevention for a number of reasons, such as the unpredictability of the molecular genetic and immunological characteristics of new epidemic and pandemic strains of influenza A virus, is not able to provide full protection of the population against viral infections. In addition due to the increasing resistance among influenza A viruses, the effectiveness of existing commercial antiviral drugs has significantly decreased. Therefore in order to prevent the spread of infectious agents including viruses special attention is currently given to the development and introduction of low-toxic and highly effective drugs into medical practice. Infectious agents are susceptible to iodine-containing drugs from nature and the formation of acquired resistance to them is not typical; therefore iodine preparations still occupy a leading place among the present-day antiseptics.

Methods: The paper presents the results of studies on the antiviral effect of iodinebased coordination compound under the working name R8 against influenza A/FPV/Waybrige/78 (H7N7) in in vitro experiments. The antiviral activity of R8 against influenza A/H7N7 was determined according to virus inhibition and therapeutic schemes. The next step was to determine the mechanism of R8 action against the influenza A virus.

Results: In this study, we found that R8 possesses significant virus-inhibiting activity against influenza A/H7N7 at concentrations from 1.97 to 0.49 mg/ml. In these concentrations, R8 completely inhibited replication of 100 infectious doses of influenza A virus. In the study of therapeutic activity at the same concentrations, R8 exhibited little efficacy against 100 infectious doses of influenza A/H7N7, the maximum decrease in infectivity titer was observed at 47.7%, compared to the positive control. Mechanism studies identified that despite the activity of the tested compound R8 in the early stages of the influenza virus life cycle, haemagglutinin (HA) is not a target for R8. Conclusions: The new coordination compound R8 which we have synthesized on the basis of molecular iodine has antiviral activity against influenza A/H7N7. Antiviral effect of R8 is most strongly manifested when the virus is pre-incubated with the drug, which indicates the potential of the tested compound as a virus-inhibiting agent.

Keywords: influenza A virus, antiviral activity, iodine, cell culture.